株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

卵管癌 : パイプライン製品の分析

Fallopian Tube Cancer - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 229740
出版日 ページ情報 英文 1496 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.77円で換算しております。
卵管癌 : パイプライン製品の分析 Fallopian Tube Cancer - Pipeline Review, H1 2020
出版日: 2020年04月30日 ページ情報: 英文 1496 Pages
概要

卵管癌とは、卵管(ファロピウス管)--卵巣と子宮をつなぐ管--で発症する癌で、非常にまれにしか発症しません。一般的な症状として、不正出血(特に閉経後)や、腹部の痛みや圧迫感、異常な(白色/透明/桃色の)膣分泌物、骨盤腔内腫瘤などが挙げられ、それらが患者の2/3を占めています。通常は、癌細胞が人体の他の部分(卵巣、子宮内膜など)から卵管へと転移することで発症します。卵巣癌の治療法は、年齢や出産の意志、腫瘍の種類・病期により変わります。通常は、化学療法の後で外科手術が実施されます。

当レポートでは、世界各国での卵管癌(ファロピウス管癌)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

卵管癌の概要

治療薬の開発

卵管癌:治療薬の評価

卵管癌治療薬の開発に従事している企業

薬剤のプロファイル

卵管癌治療薬:開発が休止状態の製品

卵管癌治療薬:開発が中止された製品

卵管癌関連製品の開発のマイルストーン

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Fallopian Tube Cancer, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Fallopian Tube Cancer - Pipeline by AB Science SA, H1 2020
  • Fallopian Tube Cancer - Pipeline by AbbVie Inc, H1 2020
  • Fallopian Tube Cancer - Pipeline by ADC Therapeutics SA, H1 2020
  • Fallopian Tube Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020
  • Fallopian Tube Cancer - Pipeline by AiVita Biomedical Inc, H1 2020
  • Fallopian Tube Cancer - Pipeline by Aldeyra Therapeutics Inc, H1 2020
  • Fallopian Tube Cancer - Pipeline by Amgen Inc, H1 2020
  • Fallopian Tube Cancer - Pipeline by Anew Oncology Inc, H1 2020
  • Fallopian Tube Cancer - Pipeline by Apexigen Inc, H1 2020

List of Figures

  • Number of Products under Development for Fallopian Tube Cancer, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12163IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Pipeline Review, H1 2020, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.

Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 20, 72, 52, 2, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 8 and 1 molecules, respectively.

Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
    • Fallopian Tube Cancer - Overview
    • Fallopian Tube Cancer - Therapeutics Development
    • Fallopian Tube Cancer - Therapeutics Assessment
    • Fallopian Tube Cancer - Companies Involved in Therapeutics Development
    • Fallopian Tube Cancer - Drug Profiles
    • Fallopian Tube Cancer - Dormant Projects
    • Fallopian Tube Cancer - Discontinued Products
    • Fallopian Tube Cancer - Product Development Milestones
    • Appendix